Physician profile
Jonathan Galli
NPI 1306139159
$5,410.10
in general payments reported to CMS, 2019-2025
25 companies · $1,980 in 2025
The $1,980 reported for 2025 was more than what 86% of Critical Care Medicine (Internal Medicine) providers received nationally (typical 2025 total: $189).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $99.99 · 2021: $26.88 · 2023: $213 · 2024: $3,090 · 2025: $1,980.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,361 · Consulting Fee: $1,836 · Education: $86.66.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,360.57 |
| Consulting Fee | $1,836.00 |
| Education | $86.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $1,984.48 | 2023-2025 | |
| Glaxosmithkline, LLC. | $1,043.53 | 2023-2025 | Nucala, Arexvy, Trelegy Ellipta |
| Astrazeneca Pharmaceuticals Lp | $628.22 | 2023-2025 | Tezspire, Fasenra, Airsupra |
| Regeneron Healthcare Solutions, INC. | $341.21 | 2024-2025 | Dupixent |
| Actelion Pharmaceuticals US, INC. | $268.26 | 2021-2025 | Uptravi, Opsumit, Opsynvi |
| Genentech USA, INC. | $169.47 | 2019-2025 | Xolair |
| Amgen INC. | $115.48 | 2024-2025 | Tezspire |
| Harmony Biosciences LLC | $106.07 | 2023-2025 | Wakix |
| Philips North America LLC | $104.29 | 2024-2025 | (Ak6) Vest Therapy, Vest Therapy Und |
| United Therapeutics Corporation | $102.18 | 2023-2025 | Tyvaso, Tyvaso |
| Ani Pharmaceuticals, INC. | $69.46 | 2025 | Purified Cortrophin Gel |
| Boehringer Ingelheim Pharmaceuticals, INC. | $63.61 | 2024-2025 | Ofev, Stiolto Respimat, Spiriva Respimat |
| Verona Pharma, INC. | $57.27 | 2025 | Ohtuvayre |
| Insmed, INC. | $56.33 | 2024-2025 | Arikayce, Brinsupri |
| Bayer Healthcare Pharmaceuticals INC. | $52.50 | 2024-2025 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Jazz Pharmaceuticals INC. | $51.84 | 2023-2024 | |
| Becton, Dickinson and Company | $47.78 | 2025 | Hemosphere |
| Avadel Cns Pharmaceuticals, LLC | $35.71 | 2024-2025 | Lumryz |
| 3b Medical, INC. | $18.25 | 2024 | Luna |
| Pharming Healthcare, INC. | $16.51 | 2023 | Ruconest |
| Vifor Pharma, INC. | $16.49 | 2025 | Veltassa |
| Mylan Specialty L.P. | $16.10 | 2024 | Yupelri |
| Axsome Therapeutics, INC. | $15.71 | 2025 | Sunosi |
| Inspire Medical Systems, INC. | $14.74 | 2024 | Inspire |
| Breas Medical, INC. | $14.61 | 2024 | Vivo 45 Ls |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jonathan Galli listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.